于健，北京航空航天大学医学科学与工程学院教授、博士生导师，北京市生物医学工程高精尖创新中心高级研究员，医工百人特聘研究员。清华大学博士，加州大学圣迭戈分校博士后。依托国家级医学攻关产教融合平台、高性能计算平台及北京市高精尖创新中心，聚焦癌症、免疫与神经等重大疾病，构建了以多组学与人工智能为核心的创新诊疗研究体系。在 J Clin Invest、Clin Cancer Res、Leukemia、PNAS 等期刊发表多篇论文，获多项发明专利，并推动抗癌抗体药物实现亿元级临床转化。
包括但不限于：
1. 多组学与药物发现：基于单细胞逆向扰动组学，整合“疾病-基因-药物”多维数据，构建从“致病细胞→候选药物→疗效验证→机制解析”的完整研究链条，致力于开发复杂疾病治疗新策略，揭示药物作用机制并挖掘新靶点。
2. 超敏蛋白靶标定量：融合单分子免疫荧光、微流控芯片、高分辨率成像与AI图像识别技术，实现飞克/毫升级别的蛋白质检测灵敏度，可精确定量痕量样本中的目标蛋白，为生命科学研究、疾病诊断、治疗监测及药物开发提供关键技术支撑。
1. Wang Y., Yu J#, Gao L#. Targeting Intratumoral Bacteria for Cancer Nanotherapeutics. ACS Appl Mater Interfaces 2025. 10.1021/acsami.5c16720.（IF 8.2; 中科院 2 区）
2. Wang Y, Wang X, Zheng Q, Fu Z, Jiang J, Yu J#, Gao L#. Targeted therapy for triple-negative breast cancer via a membrane-encased multi-active iron-sulfur nanoinducer. Nano Research 2025; 18: 94907969.（IF 9.0; 中科院 1 区 Top）
3. Feng X, Chen B, Yang Y, Dong L, Liu C, Yang Y, Hou P, Zheng D, Wang C, Kong Y, Yu J#, Sui L#. CD34 in preeclampsia: The role of endothelial cell pyroptosis and regulation by melatonin via melatonin membrane receptor 1. Int J Biol Macromol. 2025; 318: 145188.（IF 8.5; 中科院 2 区 Top）
4. Liu Z, Wu C, Yao Z, Wang Y, Yu Z, Yu J. Targeting lipid metabolism overcomes BTK inhibitor resistance in diffuse large B-cell lymphoma. Med. Nov. Technol. Devices 2024; 22: 100295.（中国科技期刊卓越行动计划高起点新刊; ESCI）
5. Liu Z, Yu J#, Zhao ZJ#, Shi H#, Kashyap MK#. Editorial: Linking cellular metabolism to hematological malignancies, volume II. Front Oncol. 2024; 14: 1387249.（IF 3.3; 中科院 3 区）
6. Chen W, Shi H, Liu Z, Yang F, Liu J, Zhang L, Wu Y, Xia Y, Ou Y, Li R, Zhang T, Zhang J, Ke X, Hu K, Yu J. Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy. Clin Cancer Res. 2023; 29(8): 1484-1495.（IF 13.801; 中科院 1 区 Top）
7. Liu J, Liu Z, Zhang J, Chen X, Chen J, Sui L, Yu J. Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner. Pharmaceutics 2022; 14(9): 1876.（IF 6.525; 中科院 3 区）
8. Liu J, Zhang F, Yu J#, Zhao Q#. Programmed death-ligand 1 expression on CD22-specific chimeric antigen receptor-modified T cells weakens antitumor potential. MedComm 2022; 3(2): e140.（IF 9.90; 中科院 1 区 Top）
9. Liu Z, Liu J, Zhang T, Li L, Zhang S, Jia H, Xia Y, Shi M, Zhang J, Yue S, Chen X, Yu J. Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma. BMC Cancer 2021; 21(1): 732.（IF 4.638; 中科院 3 区）
10. Zhang D, Guo Y, Zhao Y, Yu L, Chang Z, Pei H, Huang J, Chen C, Xue H, Xu X, Pan Y, Li N, Zhu C, Zhao ZJ, Yu J#, Chen Y#. Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression. Microb Cell Fact. 2021; 20(1): 67.（IF 6.352; 中科院 2 区）
11. Liu J, Yan W, Liu Z, Han Y, Xia Y, Yu J. A colloidal gold-based immunochromatographic strip for rapid detection of SARS-CoV-2 antibodies after vaccination. Med. Nov. Technol. Devices 2021; 11: 100084.（中国科技期刊卓越行动计划高起点新刊; ESCI）
12. Liu Z, Liu J, Zhang T, Shi M, Chen X, Chen Y, Yu J. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. Pharmacol Res. 2020; 151: 104512.（IF 10.334; 中科院 1 区 Top）
13. Yu J, Chen L, Cui B, Wu C, Choi MY, Chen Y, et al. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia 2017; 31(6): 1333-1339.（IF 12.883; 中科院 1 区 Top）
14. Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, et al. Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017; 31(12): 2608-2614.（IF 12.883; 中科院 1 区 Top）
15. Yu J, Chen L, Cui B, Widhopf GF, 2nd, Shen Z, Wu R, et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016; 126(2): 585-598.（IF 19.456; 中科院 1 区 Top）
16. Lu D#, Choi MY#, Yu J#, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA. 2011; 108(32): 13253-13257.（IF 9.58; 中科院 1 区 Top）
1. 于健，刘佳，刘卓君；依鲁替尼作为血管抑制剂的作用、降低其副作用的药物及其用途；专利号：ZL202010668072.9；授权日：2022.06.24.
2. Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George Widhopf and Charles Prussak; Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis; International Publication Number: WO 2014/031174 A1; International Publication Date: Feb 27, 2014.
3. 袁中一，于健，李东阳，杨晟；高效表达D-氨基酸氧化酶的甲醇酵母，其构建及发酵方法；专利号：ZL01132380.9；授权日：2004.03.10.